TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11983637

Group type: EXPERIMENTAL
Intervention: Exercise classes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education talks
Number of subjects: 0
Study: 9445297

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (age-matched children with asthma, never treated with corticosteroids for more than 14 days)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study: 7841058

Group type: EXPERIMENTAL
Intervention: Audiotape group (received a copy of the tape to play at home)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (did not receive a copy of the tape)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Audiotape group (poor-prognosis patients)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (non-tape controls)
Number of subjects: 117
Study: 2133623

Group type: EXPERIMENTAL
Intervention: 20 mmol Mg‐aspartate‐HCl/d for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 24
Study: 383254

Group type: EXPERIMENTAL
Intervention: CVMF (cyclophosphamide, vinblastine, methotrexate, and 5‐fluorouracil)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CAMF (cyclophosphamide, adriamycin, methotrexate, and 5‐fluorouracil)
Number of subjects: 108
Study: 31748250

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic resonance‐guided focused ultrasound (tcMRgFUS) thalamotomy
Number of subjects: 0
Study: 27806010

Group type: EXPERIMENTAL
Intervention: Experimental warm-up (8 × 50 m at 98-102% of critical velocity)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control warm-up (4 × 25 m race-pace set)
Number of subjects: 13
Study: 25851460

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24028942

Group type: EXPERIMENTAL
Intervention: MMM intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active‐placebo comparison intervention
Number of subjects: 0
Study: 22319896

Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 2 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 5 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 10 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep breathing (DB) exercise for 2, 5, and 10 minutes
Number of subjects: 12
Study: 19195651

Group type: EXPERIMENTAL
Intervention: Dorsal splint
Number of subjects: 72

Group type: COMPARATOR
Intervention: Complete cast
Number of subjects: 72
Study: 17080543

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both acupuncture and physical therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study: 15175836

Group type: EXPERIMENTAL
Intervention: 86Y-DOTA-Phe1-Tyr3-octreotide (13.32 GBq, three cycles of 4.44 GBq each)
Number of subjects: 2

Group type: COMPARATOR
Intervention: 111In-pentetreotide
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both 86Y-DOTA-Phe1-Tyr3-octreotide and 111In-pentetreotide
Number of subjects: 2
Study: 11557462

Group type: EXPERIMENTAL
Intervention: Tenofovir DF 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenofovir DF 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenofovir DF 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9783499

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 317

Group type: COMPARATOR
Intervention: Men
Number of subjects: 317
Study: 7841749

Group type: EXPERIMENTAL
Intervention: Tripterygiitotorum (T II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no immunosuppressive agents)
Number of subjects: 30
Study: 3074295

Group type: EXPERIMENTAL
Intervention: Low protein diet with standard antihypertensive therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril administration (25‐50 mg/day) for 4 weeks
Number of subjects: 12
Study: 31704275

Group type: EXPERIMENTAL
Intervention: Transcranial infrared brain stimulation (TIBS), a form of photobiomodulation (PBM), details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group), details not specified.
Number of subjects: 0
Study: 31315657

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Ecologic® Barrier; 2.5 × 10^9 colony forming units/g; 2 g; daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29191799

Group type: EXPERIMENTAL
Intervention: Web-based intervention website addressing barriers to organ donation through videos; no specific dosage or duration mentioned.
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Web-based intervention website; no specific dosage or duration mentioned.
Number of subjects: 1415
Study: 24633624

Group type: COMPARATOR
Intervention: BCAA-enriched nutrient mixture (BCAA-EN) in Study 1
Number of subjects: 92

Group type: COMPARATOR
Intervention: BCAA-enriched nutrient mixture (BCAA-EN) in Study 2
Number of subjects: 92

Group type: COMPARATOR
Intervention: BCAA group in Study 2
Number of subjects: 92
Study: 23121600

Group type: EXPERIMENTAL
Intervention: Goal-oriented action sequences
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deferred imitation assessment
Number of subjects: 40
Study: 21368061

Group type: EXPERIMENTAL
Intervention: Executing waving movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: No concurrent motor execution (baseline)
Number of subjects: 0
Study: 19501786

Group type: EXPERIMENTAL
Intervention: High confederate's food intake
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low confederate's food intake
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unsociable confederate's sociability
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sociable confederate's sociability
Number of subjects: 100
Study: 16810002

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.05 mg . kg(‐1) . h(‐1), approximately 3 mg/h)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 49
Study: 15502035

Group type: EXPERIMENTAL
Intervention: 8 mg of hyperbaric bupivacaine 0.5% (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mg of hyperbaric levobupivacaine 0.5% (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12 mg of hyperbaric ropivacaine 0.5% (n = 20)
Number of subjects: 60
Study: 11676331

Group type: COMPARATOR
Intervention: Triple-drug regimen (lansoprazole, clarithromycin, secnidazole)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quadruple-drug regimen (lansoprazole, amoxycillin, colloidal bismuth subcitrate, secnidazole)
Number of subjects: 64
Study: 9634207

Group type: EXPERIMENTAL
Intervention: HIV encephalitis observed in all centres
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Categories of exposure
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Toxoplasmosis, PML, and cryptococcal infection
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Anti-retroviral treatment (Zidovudine)
Number of subjects: 1144
Study: 8202031

Group type: EXPERIMENTAL
Intervention: etoposide (VP-16)
Number of subjects: 0

Group type: COMPARATOR
Intervention: vinblastine
Number of subjects: 0
Study: 3664912

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study: 29852853

Group type: EXPERIMENTAL
Intervention: Staircase alveolar recruitment manoeuvres with individually titrated PEEP (maximum 40 cmH2O) and peak pressures (maximum 55 cmH2O).
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Staircase alveolar recruitment manoeuvres with individually titrated PEEP and permissive hypercapnia.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation following the ARDSNet-ARMA trial protocol.
Number of subjects: 340
Study: 27401591

Group type: EXPERIMENTAL
Intervention: Exclusive commercial e-cigarette use
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dual-use of commercial e-cigarettes and usual cigarette brand
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Discontinued use of all tobacco or nicotine products
Number of subjects: 105

Group type: COMPARATOR
Intervention: Dual users
Number of subjects: 105
Study: 24625034

Group type: EXPERIMENTAL
Intervention: Proximal phalanx hemiarthroplasty (AnaToemic, Arthrex Ltd., Sheffield, UK)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study: 23529285

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20961382

Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1% Hexetidine product (positive control)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 30
Study: 19042322

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviorally-based treatment for AOSUD
Number of subjects: 50
Study: 12036665

Group type: EXPERIMENTAL
Intervention: Evening dosing of latanoprost 0.005%/timolol maleate 0.5%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morning dosing of latanoprost 0.005%/timolol maleate 0.5%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Timolol maleate given twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Evening dosing of latanoprost/timolol
Number of subjects: 36
Study: 9848556

Group type: EXPERIMENTAL
Intervention: Kessler suture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strickland suture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Robertson suture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Becker suture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volar placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dorsal placement
Number of subjects: 40
Study: 7972188

Group type: EXPERIMENTAL
Intervention: Inpatient accommodation for oncology patients receiving radiotherapy treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holistic approach to evaluate and cater for the effects of cancer on individuals
Number of subjects: 0
Study: 2689909

Group type: EXPERIMENTAL
Intervention: High dose morphinic administered for induction and maintenance of anesthesia without further analgesic and/or narcotic supplement.
Number of subjects: 18
Study: 769772

Group type: EXPERIMENTAL
Intervention: L-dopa (up to 1250 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30835911

Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM) at a dosage of 380 U/kg/day for 6 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional therapy (control arm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM)
Number of subjects: 100
Study: 28817370

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Gemcitabine alone (Gem)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: GemErlo
Number of subjects: 436

Group type: COMPARATOR
Intervention: Gem
Number of subjects: 436
Study: 25362513

Group type: EXPERIMENTAL
Intervention: Chewing gum (Group-C)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (Group-NC)
Number of subjects: 67
Study: 24041815

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii 50 mg/kg every 12 h
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 21788997

Group type: EXPERIMENTAL
Intervention: Sarsasapogenin plus risperidone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 80
Study: 19328264

Group type: EXPERIMENTAL
Intervention: Low-fat eating plan delivered by registered dietitians with behavioral, cognitive, and motivational counseling techniques.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat eating plan intervention group.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 16753687

Group type: EXPERIMENTAL
Intervention: 1 IOVE capsule per day (Group 1; n = 562)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: 2 IOVE capsules per day (Group 2; n = 518)
Number of subjects: 1080
Study: 15484298

Group type: EXPERIMENTAL
Intervention: Oxymatrine capsule (group A)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 144
Study: 11777288

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg orally daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ranitidine (50 mg intravenously four times daily)
Number of subjects: 92
Study: 9253573

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 600 IU kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 8512837

Group type: EXPERIMENTAL
Intervention: Sterile transparent dressing (Venigard, Consolidated Medical Equipment, London)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐sterile tape (Mefix, Molnlycke, Sweden)
Number of subjects: 0
Study: 30614286

Group type: EXPERIMENTAL
Intervention: Lidocaine plaster (700 mg)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 363

Group type: COMPARATOR
Intervention: Lidocaine plaster vs Placebo
Number of subjects: 363
Study: 29547163

Group type: EXPERIMENTAL
Intervention: Mobilization of the outer cavernous sinus membrane
Number of subjects: 94

Group type: COMPARATOR
Intervention: Direct opening of the dura without cavernous sinus dissection
Number of subjects: 94
Study: 27389172

Group type: EXPERIMENTAL
Intervention: HRV-16 inoculation in seronegative subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HRV-16 inoculation in seropositive subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HRV-16 inoculation in both sexes
Number of subjects: 40
Study: 24863037

Group type: EXPERIMENTAL
Intervention: 1.4% LSO toothpaste
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 1.4% LSO gel
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.8% LSO mouthwash
Number of subjects: 81

Group type: COMPARATOR
Intervention: 1% chlorhexidine gel
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 81
Study: 22497874

Group type: EXPERIMENTAL
Intervention: RIX4414 (Rotarix™)
Number of subjects: 10708
Study: 21078493

Group type: EXPERIMENTAL
Intervention: anti-dsDNA antibodies
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: antinucleosome antibodies
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: anti-C1q antibodies
Number of subjects: 245
Study: 18647285

Group type: EXPERIMENTAL
Intervention: AFI
Number of subjects: 167

Group type: COMPARATOR
Intervention: WL
Number of subjects: 167
Study: 16941030

Group type: EXPERIMENTAL
Intervention: Celecoxib, 400 mg b.i.d.
Number of subjects: 7968

Group type: COMPARATOR
Intervention: Diclofenac, 75 mg b.i.d.
Number of subjects: 7968

Group type: COMPARATOR
Intervention: Ibuprofen, 800 mg three times a day.
Number of subjects: 7968
Study: 13130321

Group type: EXPERIMENTAL
Intervention: 6-week exercise program with active exercise, muscle stretching, and treadmill walking
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study: 10935770

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 9361575

Group type: EXPERIMENTAL
Intervention: Intensive case management by culturally sensitive community health educators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 1489126

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (28 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled torasemide (28 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3563116

Group type: EXPERIMENTAL
Intervention: Oxitropium 100 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxitropium 200 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxitropium 300 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fenoterol 400 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxitropium 200 micrograms plus Fenoterol 400 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxitropium 200 micrograms and 300 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fenoterol plus Oxitropium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30646197

Group type: EXPERIMENTAL
Intervention: Manual therapy/individualized exercise
Number of subjects: 259

Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 259

Group type: COMPARATOR
Intervention: Group exercise
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 259
Study: 30286707

Group type: EXPERIMENTAL
Intervention: Higher peer specialist engagement
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lower peer specialist engagement
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 26671629

Group type: EXPERIMENTAL
Intervention: VR simulation training (7.5 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (4.5 hours of lectures)
Number of subjects: 18
Study: 24561636

Group type: EXPERIMENTAL
Intervention: 5-week neck strengthening intervention performed twice per week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (10 semiprofessional players)
Number of subjects: 25
Study: 23164333

Group type: EXPERIMENTAL
Intervention: Single Tooth Anesthesia System (STA System)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional syringe technique
Number of subjects: 100
Study: 19965781

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 17389164

Group type: EXPERIMENTAL
Intervention: PEP + FET
Number of subjects: 32

Group type: COMPARATOR
Intervention: FET
Number of subjects: 32
Study: 16127682

Group type: EXPERIMENTAL
Intervention: Extended transthoracic oesophagectomy
Number of subjects: 50
Study: 12401635

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 50
Study: 10087420

Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate) 2 g daily until delivery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate)
Number of subjects: 23
Study: 8628838

Group type: EXPERIMENTAL
Intervention: Amalgambond Plus with HPA
Number of subjects: 0
Study: 2333739

Group type: EXPERIMENTAL
Intervention: Formula with 1.3 g protein/dl and 55:45 whey: casein ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with 1.4 g/dl protein; 55:45 whey: casein ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with 1.5 g/dl protein; 55:45 whey: casein ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with 1.4 g/dl protein; 60:40 whey: casein ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with 1.4 g/dl protein; 20:80 whey: casein ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All formulas containing 0.7 mg iron and 0.7 mg zinc/dl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 0
Study: 453775

Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) 2 mg t.i.d.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methyldopa (MD) 250 mg t.i.d.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Methyldopa (MD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Clonidine (C)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Propranolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Diuretic
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30183409

Group type: EXPERIMENTAL
Intervention: Self-care education (4 sessions of 45 minutes each)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 70
Study: 27640922

Group type: EXPERIMENTAL
Intervention: Standard dose shockwave therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham dose
Number of subjects: 28
Study: 26299931

Group type: EXPERIMENTAL
Intervention: 1100F-HMP1% toothpaste
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1100ppm F (1100F) toothpaste
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (no F or HMP)
Number of subjects: 12
Study: 22781558

Group type: EXPERIMENTAL
Intervention: NIV + nebulizer group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 20471117

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin loading before PCI
Number of subjects: 445

Group type: COMPARATOR
Intervention: No statin treatment before PCI (control group)
Number of subjects: 445
Study: 19491814

Group type: EXPERIMENTAL
Intervention: Ladasten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17260161

Group type: EXPERIMENTAL
Intervention: Induction of hyperammonemia by administration of a solution mimicking the amino acid composition of haemoglobin (60)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (24)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Induction of hyperammonemia
Number of subjects: 84
Study: 14696754

Group type: EXPERIMENTAL
Intervention: 30 or 60 mg folic acid with or without vitamins B6 and B12 for eight weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Intravenous folinic acid given alone or with serine for eight weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Matching placebos for both protocols
Number of subjects: 114